MARTINSRIED, Germany and MUNICH, Germany and WALTHAM, Mass. and BOSTON and PRINCETON, N.J., Oct. 28 /PRNewswire-FirstCall/ -- GPC Biotech AG today announced that the Company will hold an analyst and press meeting in Frankfurt, Germany to discuss financial results for the third quarter and first nine months of 2005 and to provide a business update.
The meeting, which will be conducted in English, will be held Thursday, November 3, 2005 at 14:00 CET/8:00 AM EST at the Maritim Hotel in Frankfurt.
The meeting will also be accessible via telephone or webcast.
The live webcast, including synchronized slides, will be available on the GPC Biotech Web site at http://www.gpc-biotech.com. A replay will be available via the Web site following the live event.
Dial-in numbers for the analyst and press meeting are as follows: European participants: 0049 (0)69 500 71846 U.S. participants: 1-866-362-5158 (toll-free) Please dial in 10 minutes before the beginning of the meeting.
GPC Biotech AG is a biopharmaceutical company discovering and developing new anticancer drugs. The Company’s lead product candidate -- satraplatin -- is currently in a Phase 3 registrational trial as a second-line chemotherapy treatment in hormone-refractory prostate cancer following completion of a Special Protocol Assessment by the U.S. FDA and receipt of a Scientific Advice letter from the European central regulatory authority, EMEA. The FDA has also granted fast track designation to satraplatin for this indication. Other anticancer programs include: a monoclonal antibody with a novel mechanism-of- action against a variety of lymphoid tumors, currently in Phase 1 clinical development, and a small molecule broad-spectrum cell cycle inhibitors program, currently in pre-clinical development. The Company also has a number of drug discovery programs that leverage its expertise in kinase inhibitors. GPC Biotech has a multi-year alliance with ALTANA Pharma AG working with the ALTANA Research Institute in the U.S., which provides GPC Biotech with revenues through mid-2007. GPC Biotech AG is headquartered in Martinsried/Munich (Germany). The Company’s wholly owned U.S. subsidiary has research and development sites in Waltham, Massachusetts and Princeton, New Jersey. For additional information, please visit the Company’s Web site at http://www.gpc-biotech.com.
GPC Biotech AG
CONTACT: Martin Braendle, Associate Director, Investor Relations &Corporate Communications of GPC Biotech AG, +49-89-8565-2693,ir@gpc-biotech.com; or In the U.S.: Laurie Doyle, Associate Director,Investor Relations & Corporate Communications, Phone: +1-781-890-9007, ext.267, usinvestors@gpc-biotech.com
Web site: http://www.gpc-biotech.com/
